Download PDF
Hamostaseologie 1985; 05(05/06): 178-184
DOI: 10.1055/s-0038-1655126
Originalarbeiten
Schattauer GmbH

Biologische Grundlagen einer Antikoagulantienbehandlung bei Tumorkrankheiten

L. R. Zacharski
1   Department of Medicine, Dartmouth Medical School and the Veterans Administration Medical Center, White River Junction/USA
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Bastida E, Ordinas A, Jamieson G. A. Differing platelet aggregating effects by two tumor cell lines: absence of role for plateletderived ADP. Amer. J. Hematol. 11: 367-378 1981;
    CrossrefPubMedGoogle Scholar
  • 2 Billroth T. Lectures on Surgical Pathology and Therapeutics, translated from the. 8th. ed. London: New Sydenham Society; 1878
    Google Scholar
  • 3 Brown J. M. A study of the mechanisms by which anticoagulation with warfarin inhibits blood borne metastasis. Cancer Res. 33: 1217-1224 1973;
    PubMedGoogle Scholar
  • 4 Brugarolas A, Elias E. G, Takita H, Mink I. B, Mittelman A, Ambrus J. L. Blood coagulation and fibrinolysis in patients with carcinoma of the lung. J. Med. 04: 96-105 1973;
    CrossrefPubMedGoogle Scholar
  • 5 Byrd R. B, Divertie M. B, Spittell Jr. J. A. Bronchogenic carcinoma and thromboembolic disease. J. Am. Med. Assoc. 202: 1019-1022 1967;
    CrossrefPubMedGoogle Scholar
  • 6 Carmel R. J, Brown J. M. The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastasis in mice. Cancer Res. 37: 145-151 1977;
    PubMedGoogle Scholar
  • 7 Chahinian A. P, Ware J. H, Zimmer B, Comis R. L, Perry M. C, Hirsh V, Skarin A. T, Raich P. C, Weiss R. B, Green M, Carey R. W. Update on anticoagulation with warfarin and on alternating chemotherapy in extensive small cell carcinoma of the lung. Proc. Am. Soc. Clin. Oncol. 04: 191 1985;
    PubMedGoogle Scholar
  • 8 Colucci M, Giavazzi R, Alessandri G, Semeraro N, Montavani A, Donati M. B. Procoagulant (tissue factor) activity is higher in cells from murine sarcoma sublines with lower metastatic pötentia. Thrombos. Haemostas. 46: 33 1981;
    PubMedGoogle Scholar
  • 9 Delaini F, Colucci M, Vitti GDeBellis, Locati D, Poggi A, Semeraro N, Donati M. B. Cancer cell procoagulant: a novel vitamin K-dependent activity. Thromb. Res. 24: 263-266 1981;
    CrossrefPubMedGoogle Scholar
  • 10 Donati M. B, Poggi A, Semeraro N. Coagulation and malignancy. In: Recent Advances in Blood Coagulation. Vol. 3. Poller L. (Ed.). Churchill-Livingstone; New York: 1981: 227.
    Google Scholar
  • 11 D’Souza D. P, Daly L, Thornes R. D. Increased survival in advanced breast cancer with warfarin, B. C. B. and levamisole as adjuvants to chemotherapy. Ir. Med. J. 71: 605-608 1978;
    PubMedGoogle Scholar
  • 12 Dvorak H. F, Orenstein N. S, Dvorak A. M. Tumor-secreted mediators and the tumor microenvironment: relationship to immunologic surveillance. Lymphokines 02: 203-233 1981;
    PubMedGoogle Scholar
  • 13 Edwards R. L, Rickles F. R, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J. Lab. Clin. Med. 98: 917-928 1981;
    PubMedGoogle Scholar
  • 14 Gilbert L, Gordon S. G. Relationship between cellular procoagulant activity and metastatic capacity of B-16 mouse melanoma variants. Cancer Res. 43: 536-540 1983;
    PubMedGoogle Scholar
  • 15 Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. J. Lab. Clin. Med. 16: 369-372 1930;
    PubMedGoogle Scholar
  • 16 Hagedorn A. B, Bowie E. J. W, Elvebach L. R, Owen Jr. C. A. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin. Proc. 49: 647-653 1974;
    PubMedGoogle Scholar
  • 17 Hara Y, Steinner M, Baldini M. B. Platelets as a source of growth-promoting factor(s) for tumor cells. Cancer Res. 40: 1212-1216 1980;
    PubMedGoogle Scholar
  • 18 Henderson W. G, Zacharski L. R, Spiegel P. K, Rickles F. R, Forman W. B, Cornell Jr. C. J, Forcier R. J, Edwards R. L, Headley D, Kim S-H, O’Donnell J. F, O’Dell R, Tornyos K, Kwaan H. C. Comparison of local versus central tumor measurements in a multicenter clinical trial. Am. J. Clin. Oncol. 07: 705-712 1984;
    CrossrefPubMedGoogle Scholar
  • 19 Hilgard P, Thornes R. D. Anticoagulants in the treatment of cancer. Eur. J. Cancer 12: 755-762 1976;
    CrossrefPubMedGoogle Scholar
  • 20 Honn K. V, Busse W. D, Sloane B. F. Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochem. Pharmacol 32: 1-11 1983;
    CrossrefPubMedGoogle Scholar
  • 21 Jones D. S, Wallace A. C, Fraser E. E. Sequence of events in experimental metastases of Walker 256 tumor: light, immunofluorescent and electron microscopic observations. J. Natl. Cancer Inst. 46: 493-504 1971;
    PubMedGoogle Scholar
  • 22 Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastasis. Ann. Int. Med. 95: 636-641 1981;
    CrossrefPubMedGoogle Scholar
  • 23 Kepner N, Greasy G, Lipton A. Platelets as a source of cell proliferating activity. In: Platelets: A Multidisciplinary Approach. DeGaetano G, Garattini S. (Eds.). Raven Press; New York: 1978: 205.
    Google Scholar
  • 24 Maat B, Hilgard P. Critical analysis of experimental models for the antimetastatic effects of anticoagulants. In: Clinical Experimental Aspects. Heilman K, Hilgard P, Eccles S. (Eds.). Martinus Nijhoff; Boston: 1980: 109-115.
    Google Scholar
  • 25 Marcum J. M, McGill M, Bastida E, Ordinas A, Jamieson G. A. The interaction of platelets, tumor cells and vascular subendothelium. J. Lab. Clin. Med. 96: 1046-1053 1980;
    PubMedGoogle Scholar
  • 26 O’Meara R. A. Q. Coagulative properties of cancers. Ir. J. Med. Sci. 06: 474-479 1958;
    PubMedGoogle Scholar
  • 27 O’Meara R. A. Q, Jackson R. D. Cytological observations on carcinoma. Ir. J. Med. Sci. 06: 327-328 1959;
    PubMedGoogle Scholar
  • 28 O’Meara R. A. Q. Fibrin formation and tumour growth. Thrombos. Diathes. Haemorrh. (Suppl) 28: 137-142 1968;
    PubMedGoogle Scholar
  • 29 Onoda J. M, Sloane B. F, Taylor J. D, Honn K. V. Calcium channel blockers: inhibitors of tumor cell-platelet-endothelial cell interactions. In: Hemostatic Mechanisms and Metastasis. Honn K. V, Sloane B. F. (Eds.). Martinus Nijhoff; Boston: 1984: 244-258.
    Google Scholar
  • 30 Pearlstein E, Salk P. L, Yogeeswaran G, Karpatkin S. Correlation between spontaneous metastatic potential, platelet aggregating activity of cell surface extracts and cell surface sialylation in 10 metastaticvariant derivatives of a rat renal sarcoma cell line. Proc. Natl. Acad. Sci. (USA) 77: 4336-4339 1980;
    CrossrefPubMedGoogle Scholar
  • 31 Pearlstein E, Cooper L. B, Karpatkin S. Extraction and characterization of a platelet-aggregating material from SV40-transformed mouse 3T3 fibroblasts. J. Lab. Clin. Med. 93: 332-334 1979;
    PubMedGoogle Scholar
  • 32 Rickles F. R, Edwards R. L, Barb C, Cronlung M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 51: 301-307 1983;
    CrossrefPubMedGoogle Scholar
  • 33 Sack Jr. G. H, Levin J, Bell W. R. Trusseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical pathophysiologic and therapeutic features. Medicine 56: 1-37 1977;
    CrossrefPubMedGoogle Scholar
  • 34 Talmadge J. E, Starkey J. R, Stanford D. R. In vitro characteristics of metastatic variant subclones of restricted genetic origin. J. Supramol. Struct. Cell Biochem. 15: 139-151 1981;
    CrossrefPubMedGoogle Scholar
  • 35 Tanaka N, Ogawa H, Kinjo M, Kohga S, Tanaka K. Ultrastructural study of the effects of transexamic acid and urokinase on metastasis of Lewis lung carcinoma. Brit. J. Cancer 46: 428-435 1982;
    CrossrefPubMedGoogle Scholar
  • 36 Terranova T, Chiossone F. II fattore coagulazione neirattecchimento delle cellule neoplastiche immesse in circulo. Bull. Soc. Ital. Biol. Sper. 28: 1224-1225 1952;
    PubMedGoogle Scholar
  • 37 Thornes R. D. Oral anticoagulant therapy of human cancer. J. Med. 05: 83-91 1974;
    PubMedGoogle Scholar
  • 38 Thornes R. D. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer 35: 91-97 1975;
    CrossrefPubMedGoogle Scholar
  • 39 Wessler S, Gitel S. N. Warfarin from bedside to bench. New Engl. J. Med. 311: 645-652 1984;
    CrossrefPubMedGoogle Scholar
  • 40 Wood Jr. S. Mechanism of establishment of tumor metastases. In: Pathobiology Annual. Joachim H. L. (Ed.). 1971: 281 281.
    Google Scholar
  • 41 Zacharski L. R. Anticoagulation in the treatment of cancer in man. In: Malignancy and the Hemostatic System. Donati M. B, Davidson J. F, Garattini S. (Eds.). Raven Press; New York: 1981: 113-129.
    Google Scholar
  • 42 Zacharski L. R. The biologic basis for anticoagulant treatment of cancer. In: Interaction of Platelets and Tumor Cells. Jamieson G. A. (Ed.). Alan R. Liss; New York: 1982: 113-127.
    Google Scholar
  • 43 Zacharski L. R. Warfarin anticoagulation for human malignancy. In: Protective Agents in Cancer. McBrien D. C. H, Slater T. F. (Eds.). Academic Press; London: 1982: 23-36.
    Google Scholar
  • 44 Zacharski L. R. The design and execution of anticoagulant therapy trials in cancer. In: Hemostatic Mechanisms and Metastasis. Honn K. V, Sloane B. F. (Eds.). Martinus Nijhoff; Boston: 1984: 375-392.
    Google Scholar
  • 45 Zacharski L. R. Mechanisms of warfarin inhibition of cancer dissemination. In press 1985
    PubMedGoogle Scholar
  • 46 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, Cornell Jr. C. S, Forcier R. J, Harrower H. W, Johnson R. O. Rationale and experimental design for the VA Cooperative Study of anticoagulation (warfarin) in the treatment of cancer. Cancer 44: 732-741 1979;
    CrossrefPubMedGoogle Scholar
  • 47 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, Cornell Jr. C. J, Forcier R. J, Headley E, Kim S-H, O’Donnell J. F, O’Dell R, Tornyos K, Kwaan H. C. Effect of sodium warfarin on survival in small cell carcinoma of the lung. J. Am. Med. Assoc. 145: 831-835 1981;
    PubMedGoogle Scholar
  • 48 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, van Eeckhout J. P, Cornell Jr. C. J, Forcier R. J, Martin J. F. Platelets and malignancy: rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. Amer. J. Clin. Oncol. 05: 593-609 1982;
    CrossrefPubMedGoogle Scholar
  • 49 Zacharski L. R, Henderson W. G, Rickles F. R, Forman W. B, Cornell Jr. C. J, Forcier R. J, Edwards R. L, Headley E, Kim S. H, O’Donnell J. F, O’Dell R, Tornyos K, Kwaan H. C. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: final report of VA Cooperative Study # 75. Cancer 53: 2046-2052 1984;
    CrossrefPubMedGoogle Scholar
  • 50 Zacharski L. R, Schned A. R, Sorenson G. D. Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung. Cancer Res. 43: 3963-3968 1983;
    PubMedGoogle Scholar
  • 51 Zacharski L. R, Rosenstein R. Reduction of salivary tissue factor (thromboplastin) activity by warfarin therapy. Blood 53: 366-374 1979;
    PubMedGoogle Scholar